Allergan lets insults fly at hostile suitor Valeant and its 'Wizard of Oz' buyout bid

The Valeant/Allergan takeover battle was already pretty heated, with the Canadian pharma taking its latest rejected offer to Allergan shareholders. But it's getting hotter, thanks to some layoffs, an exec exit, a lawsuit, a litany of barbs from Allergan ($AGN)--and yet another Valeant ($VRX) conference call.

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); });